HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Guangzhou Pharmaceuticals Co Ltd / Equity Capital Markets

Guangzhou Pharmaceuticals Co Ltd (GPC HK)

<p>On March 31, 2021, <a href="https://www.smartkarma.com/entities/guangzhou-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:33005:1" rel="noopener">Guangzhou Pharmaceuticals Co Ltd (GPC HK)</a> submitted a prospectus to the Hong Kong Stock Exchange, which means that Guangzhou Pharmaceuticals, the fifth largest pharmaceutical distributor nationwide and the largest pharmaceutical distributor in South China, would be listed in Hong Kong in the near future. It is also worth mentioning that, as the Company submitted the IPO application, the risk points of the Company also gradually emerged considering the current competition pattern, new policies and its business performance.</p>

On March 31, 2021, Guangzhou Pharmaceuticals Co Ltd (GPC HK) submitted a prospectus to the Hong Kong Stock Exchange, which means that Guangzhou Pharmaceuticals, the fifth largest pharmaceutical distributor nationwide and the largest pharmaceutical distributor in South China, would be listed in Hong Kong in the near future. It is also worth mentioning that, as the Company submitted the IPO application, the risk points of the Company also gradually emerged considering the current competition pattern, new policies and its business performance.

Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Pre-IPO Guangzhou Pharmaceuticals - The Risk Points Gradually Emerged

As Guangzhou Pharmaceuticals submitted the IPO application, the risk points emerged considering the competition pattern, new policies and business...

Xinyao (Criss) Wang